Use of AKT / STAT3 as a target for immune checkpoint inhibitors
By developing the small molecule inhibitor ZQH2019818551220 for the AKT/STAT3 pathway, the problems of drug resistance and side effects of immune checkpoint inhibitors in lung cancer treatment have been solved, achieving a highly effective and low-toxicity tumor treatment effect.
Patent Information
- Application Number
- CN202310117664.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-12-04
- Filing Date
- 2021-12-06
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2041-12-06
AI Technical Summary
Existing immune checkpoint inhibitors have problems with acquired and primary resistance in the treatment of lung cancer, and may cause serious immune complications, lacking highly effective and low-toxicity treatment options.
The small molecule inhibitor ZQH2019818551220 of the AKT/STAT3 pathway was developed. By inhibiting the activity of the AKT/STAT3 pathway, it downregulates PD-L1 expression, blocks the binding of PD-1 and PD-L1, enhances the anti-tumor immune response of T cells, and can be used in combination with existing immune checkpoint inhibitors.
It significantly inhibits the proliferation and apoptosis of tumor cells, slows down drug resistance, enhances the effect of immunotherapy, and reduces toxic side effects.
Smart Images

Figure CN116650645B_ABST
Abstract
Description
[0001] This application is a divisional application of patent application number "2021114823502", filed on "December 6, 2021", entitled "Use of AKT / STAT3 as a target of immune checkpoint inhibitor". Technical Field
[0002] This invention belongs to the field of biomedicine, specifically relating to new uses of AKT / STAT3 inhibitors. Background Technology
[0003] Lung cancer is currently the fastest-growing malignant tumor in terms of incidence and mortality worldwide, posing the greatest threat to human health and life. Latest data shows that in 2018, 18.1 million new cancer cases were diagnosed globally, of which 11.6% were lung cancer cases; and 9.6 million cancer deaths occurred globally in 2018, of which 18.4% were due to lung cancer. In my country, 4.064 million new cancer cases were diagnosed in 2018, of which 828,100 were lung cancer cases, accounting for 20.38% of all cancer patients; and 2.4135 million cancer deaths occurred in my country in 2018, of which 657,000 were lung cancer cases, accounting for 27.22% of all cancer deaths. Based on pathological type, treatment method, and prognosis, primary lung cancer is broadly classified into non-small cell lung cancer (NSCLC) and small cell lung cancer. The former is more common, accounting for 85%-90%, and mainly includes pathological types such as lung adenocarcinoma and lung squamous cell carcinoma. To date, due to the lack of effective early diagnostic methods, 35%-40% of lung cancer patients are diagnosed at locally advanced stages, and 40%-45% have advanced lung cancer with distant metastases, thus losing the opportunity for surgical treatment. Only 15%-20% are in the early to mid-stages and are suitable for surgical treatment. Therefore, lung cancer is the malignant tumor with the worst prognosis in clinical practice.
[0004] In recent years, with the application of molecularly targeted drugs and immune checkpoint inhibitors in the clinical treatment of lung cancer, the number of available drugs for the treatment of NSCLC has increased significantly, and the treatment is more targeted than traditional chemotherapy: NSCLC patients with epidermal growth factor receptor (EGFR) gene-sensitive mutations detected in tumor tissue or blood tests are given priority for oral treatment with first-generation EGFR tyrosine kinase inhibitors (TKIs); after drug resistance, those with T790M mutations detected in tumor tissue or blood gene tests can switch to third-generation EGFR-TKIs such as osimertinib; NSCLC patients with anaplastic lymphoma kinase (ALK) gene rearrangements in tumor tissue can choose ALK tyrosine kinase inhibitors; and the positive rate of programmed death 1 ligand (PD-L1) in immunohistochemical staining results >50% can be used as an indication for first-line use of immune checkpoint inhibitors such as pembrolizumab. Existing studies have demonstrated that the application of molecularly targeted drugs such as EGFR-TKIs has increased the 5-year survival rate of NSCLC patients from 10% to 18%. However, it has also been shown that acquired resistance develops on average after 8 months of EGFR-TKI use, and some patients develop primary resistance. The clinical application of immune checkpoint inhibitors has brought new options and hope to the treatment of lung cancer, increasing the 5-year survival rate of advanced lung cancer to 23.6%.
[0005] Existing immune checkpoint inhibitors work by inhibiting and blocking PD-1 / PD-L1 molecular targets in the immune pathway, reversing tumor-induced immune escape, restoring the body's normal anti-tumor immune function, and mobilizing the body's own T lymphocytes and other immune cells to kill tumors, thereby achieving the effect of treating tumors. However, immune checkpoint inhibitors also have the problem of acquired resistance and primary resistance, and some patients may also experience severe and fatal complications such as immune-mediated pneumonia, immune-mediated myocarditis, and immune-mediated hepatitis. Therefore, researching and developing new, highly effective, and low-toxicity immune checkpoint inhibitors holds the hope for improving the clinical cure rate and survival rate of lung cancer in the future. Summary of the Invention
[0006] The purpose of this invention is to provide a new immune checkpoint inhibitor target AKT / STAT3 and to provide new uses for AKT / STAT3 inhibitors.
[0007] This invention provides the use of AKT / STAT3 as a target for immune checkpoint inhibitors.
[0008] The present invention also provides the use of AKT / STAT3 inhibitors in the preparation of medicaments for treating tumors and / or autoimmune diseases; preferably, the medicaments for treating tumors are medicaments for treating lung cancer, liver cancer, gastric cancer, cervical cancer, breast cancer, prostate cancer, nasopharyngeal carcinoma, colorectal cancer, oral cancer, or pancreatic cancer.
[0009] Furthermore, the aforementioned drugs for treating tumors and / or autoimmune diseases are drugs that restore T cell activity and enhance T cell immune responses.
[0010] Furthermore, the aforementioned drugs for treating tumors and / or autoimmune diseases are drugs that inhibit tumor cell proliferation and / or induce tumor cell apoptosis.
[0011] Furthermore, the aforementioned drugs for treating tumors and / or autoimmune diseases are drugs that inhibit the tumorigenicity of tumor cells.
[0012] The present invention also provides an N-terminal acetyl-modified polypeptide, the sequence of which is shown in SEQ ID NO. 1. Preferably, the AKT / STAT3 inhibitor is: (N-terminal)Acetyl-Ser-Glu-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Asp-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn (C-terminal).
[0013] The present invention also provides the use of the above-mentioned N-terminal acetyl-modified peptide in AKT / STAT3 inhibitors.
[0014] The present invention also provides the use of AKT / STAT3 inhibitors in the preparation of inhibitors that inhibit PD-1 / PD-L1.
[0015] Furthermore, the aforementioned inhibitors that inhibit PD-1 / PD-L1 are also inhibitors that downregulate PD-L1 expression.
[0016] Furthermore, the aforementioned inhibitors that inhibit PD-1 / PD-L1 are inhibitors that block the binding of PD-1 to PD-L1.
[0017] Furthermore, the aforementioned AKT / STAT3 inhibitors include: AKT pathway inhibitors, PI3K / AKT pathway inhibitors, and STAT3 pathway inhibitors.
[0018] Furthermore, the aforementioned AKT / STAT3 inhibitor is a polypeptide with an N-terminus modified by an acetyl group.
[0019] The present invention also provides the use of AKT / STAT3 expression level detection reagent in the preparation of tumor / or autoimmune disease screening reagent; preferably, the tumor / or autoimmune disease screening reagent is a screening reagent for lung cancer, liver cancer, gastric cancer, cervical cancer, breast cancer, prostate cancer, nasopharyngeal carcinoma, colorectal cancer, oral cancer or pancreatic cancer.
[0020] In the process of researching a novel small molecule inhibitory compound for the AKT / STAT3 pathway, ZQH2019818551220 (structure: (N-terminal) Acetyl-Ser-Glu-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Asp-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn (C-terminal), molecular weight 3149), the inventors unexpectedly discovered that this compound, in addition to inhibiting AKT / STAT3 pathway activity, can also significantly inhibit PD-L1 expression levels, thereby blocking the binding of PD-1 to PD-L1, restoring T cell activity, and thus enhancing the T cell anti-tumor immune response. In vitro experiments showed that this small molecule inhibitory compound can inhibit the in vitro proliferation of tumor cells and induce tumor cell apoptosis; in mouse lung cancer xenograft models, this small molecule inhibitory compound can significantly inhibit the tumorigenicity of lung cancer xenografts. Therefore, the AKT / STAT3 pathway is a novel immune checkpoint pathway that can be used to develop novel, highly effective, and low-toxicity immune checkpoint inhibitors for tumor immunotherapy. Furthermore, the AKT / STAT3 pathway immune checkpoint inhibitor of this invention can be used in combination with existing immune checkpoint inhibitors to block tumor immune escape through dual pathways, thereby enhancing the efficacy of immunotherapy and avoiding or / and mitigating drug resistance to single PD-1 immune checkpoint inhibitors.
[0021] Obviously, based on the above description of the present invention, and according to common technical knowledge and conventional methods in the field, various other modifications, substitutions or alterations can be made without departing from the basic technical concept of the present invention.
[0022] The following detailed embodiments further illustrate the above-described content of the present invention. However, this should not be construed as limiting the scope of the present invention to the following examples. All technologies implemented based on the above-described content of the present invention fall within the scope of the present invention. Attached Figure Description
[0023] Figure 1(A) Using the normal human bronchial epithelial cell line Beas-2B as a control, Western Blot was used to detect the PD-L1 protein expression levels of lung cancer cell lines NL9980, L9981, 95C, 95D, A549, H1299, SPC-A-1, H460, and YTMLC-90. The figure shows representative Western Blot bands and a bar chart of grayscale measurement results. (B) Using Beas-2B cells as a control, qRT-PCR was used to detect the PD-L1 mRNA levels of lung cancer cell lines NL9980, L9981, 95C, 95D, A549, H1299, SPC-A-1, H460, and YTMLC-90. *: P<0.05; ***: P<0.001.
[0024] Figure 2 The study aimed to detect (A) the changes in PD-L1 protein expression levels in H1299, NL9980, and L9981 lung cancer cells after treatment with ZQH2019818551220 at concentrations of 0, 90, 180, and 360 μM / ml for 72 hours using Western Blot; (B) the changes in PD-L1 protein expression levels in H1299, NL9980, and L9981 lung cancer cells after treatment with ZQH2019818551220 at concentrations of 360 μM / ml for 0, 24, 48, and 72 hours using Western Blot; and (C) the changes in mean fluorescence intensity of PD-L1 in H1299, NL9980, and L9981 lung cancer cells after treatment with ZQH2019818551220 at concentrations of 0, 180, and 360 μM / ml for 72 hours using flow cytometry.
[0025] Figure 3 The changes in PD-L1 mRNA levels in H1299(A), NL9980(B), and L9981(C) lung cancer cells after treatment with ZQH2019818551220 at concentrations of 0, 90, 180, and 360 μM / ml for 72 hours were detected by qRT-PCR.
[0026] Figure 4(A) Western blot analysis was performed to detect changes in AKT protein levels in H1299, NL9980, and L9981 lung cancer cells after treatment with 0, 90, 180, and 360 μM ZQH2019818551220 for 72 hours, respectively; (B) Pretreatment with 10 μM AKT agonist SC79 or the same concentration of solvent (DMSO) for 1 hour, followed by treatment with 360 μM ZQH2019818551220 or the same concentration of solvent (original water for injection) for 72 hours, forming the four treatment modes shown in the figure. Western blot analysis was performed to detect changes in p-AKT and PD-L1 protein expression levels in H1299 cells under the four different treatment modes.
[0027] Figure 5 The four treatment modalities shown in the figure are: (A) Changes in the expression levels of HIF1α, STAT3, p65, and c-jun proteins in H1299, NL9980, and L9981 lung cancer cells after treatment with 360 μM / ml ZQH2019818551220 for 72 hours; (B) Expression of nuclear and cytoplasmic STAT3 proteins in H1299, NL9980, and L9981 cells after treatment with 360 μM / ml ZQH2019818551220 for 72 hours; (C) Pretreatment with 0.5 μM / ml STAT3 agonist Colivelin or the same concentration of solvent (DMSO) for 1 hour, followed by treatment with 360 μM / ml ZQH2019818551220 or the same concentration of solvent (original water for injection) for 72 hours. Blot analysis was conducted to detect changes in the expression levels of p-STAT3 and PD-L1 proteins in H1299 cells under four different treatment modes.
[0028] Figure 6 (A) The pGL3-Basic recombinant plasmid containing the CD274 promoter region fragment was digested with restriction endonucleases Kpn I and Sac I. The results showed a target fragment band of about 1.5 kb and a vector fragment band of about 5 kb in the DNA agarose gel. (B) The spliced sequence of the target fragment was obtained by reading the forward and reverse sequencing peak diagrams using bidirectional sequencing technology. (C) Forward sequencing peak diagram of the target fragment in the CD274 promoter region in the recombinant plasmid. (D) Reverse sequencing peak diagram of the target fragment in the CD274 promoter region in the recombinant plasmid.
[0029] Figure 7(A) To detect the changes in relative fluorescence activity of H1299, NL9980, and L9981 lung cancer cells transfected with dual-luciferase reporter plasmids after treatment with 0, 90, 180, and 360 μM / ml ZQH2019818551220 for 72 hours, respectively; (B) To detect the changes in relative fluorescence activity of H1299 and L9981 lung cancer cells transfected with dual-luciferase reporter plasmids after pretreatment with 10 μM / ml AKT agonist SC79 or the same concentration of solvent (DMSO) for 1 hour, followed by treatment with 360 μM / ml AKT agonist SC79 for 72 hours, respectively. (A) Cells were treated with 0 μM ZQH2019818551220 or the same concentration of solvent (original water for injection) for 72 hours, forming the four treatment modes shown in Figure B. A dual-luciferase reporter assay was used to detect changes in relative fluorescence activity under the four different treatment modes. (C) In H1299 and L9981 cells transfected with dual-luciferase reporter plasmids, cells were pretreated with 0.5 μM / ml STAT3 agonist Colivelin or the same concentration of solvent (DMSO) for 1 hour, and then treated with 360 μM / ml ZQH2019818551220 or the same concentration of solvent (original water for injection) for 72 hours, forming the four treatment modes shown in Figure C. A dual-luciferase reporter assay was used to detect changes in relative fluorescence activity under the four different treatment modes. ***: P < 0.001.
[0030] Figure 8 To investigate the anti-tumor growth effect of ZQH2019818551220 in H1299-luc and L9981-luc transplanted tumors. (A) Tumor inoculation and administration method: The tumor was inoculated and the tumor was observed to be visible to the naked eye (tumor volume approximately 60 mm). 3 Five nude mice in the ZQH2019818551220 treatment group were administered ZQH2019818551220 via subcutaneous injection at 20 mg / kg / day for 36 days. The corresponding control group received the same dose of ZQH2019818551220 via subcutaneous injection for 36 days. The tumor volume in the H1299-luc control group reached approximately 900 mm². 3 The tumor volume in the L9981-luc control group reached approximately 500 mm. 3 (A) Nude mice were euthanized and the inoculated tumors were removed for further processing; (B) Tumor volume growth curves of the ZQH20198185512201 treatment group and the control group during 36 days of drug administration; (C) After the drug treatment ended, the tumor-bearing nude mice were anesthetized and photographed; (D) The transplanted orthotopic tumors were removed and the size and morphology of the tumors in the ZQH2019818551220 treatment group and the control group were observed and compared; (E) Comparison of tumor weight and nude mouse body weight between the ZQH2019818551220 treatment group and the control group. *: P<0.05; **: P<0.01; ***: P<0.001.
[0031] Figure 9 To detect luciferase activity in nude mice with H1299-luc and L9981-luc xenografts using in vivo imaging. (A) In nude mice inoculated with H1299-luc and L9981-luc, the distribution of orthotopic xenografts and metastatic lesions was compared between the control group and the ZQH2019818551220 drug treatment group; (B) Luciferase activity in orthotopic xenografts and metastatic lesions was statistically analyzed in each group. *: P<0.05; **: P<0.01.
[0032] Figure 10 Immunohistochemical staining was used to detect PD-L1 expression levels in tumor tissues of the L9981-luc orthotopic xenograft control group and the drug-treated group. The scale bars in the figure represent 90 μm (A) and 30 μm (B). Detailed Implementation
[0033] The raw materials and equipment used in this invention are all known products, obtained by purchasing commercially available products.
[0034] Example 1: Comparison of PD-L1 Expression Levels in Lung Cancer Cell Lines with Different Histological Origins and Metastatic Potential. The expression level of PD-L1 varies considerably among various lung cancer cell lines. Some cell lines show very low expression levels, requiring induction with interferon-γ, epidermal growth factor, etc., before they can be detected in Western blotting. Therefore, we first selected the normal human bronchial epithelial cell line Beas-2B as a control and used Western blotting to detect the PD-L1 expression levels in lung cancer cell lines NL9980, L9981, 95C, 95D, A549, H1299, SPC-A-1, H460, and YTMLC-90.
[0035] Western blot results showed that compared with normal human bronchial epithelial cells Beas-2B, the expression level of PD-L1 in lung cancer cells NL9980, L9981, 95D, and H1299 was significantly increased; while the expression level of PD-L1 in A549, SPC-A-1, and H460 cell lines was slightly increased. Figure 1A). qRT-PCR results showed that the PD-L1 mRNA levels among different cell lines were significantly different (P<0.001) according to the F test. Pairwise comparisons showed that the PD-L1 mRNA levels in NL9980, L9981, 95C, 95D, H1299, H460, YTMLC-90, and SPC-A-1 cells were significantly higher than those in Beas-2B cells. Among them, the PD-L1 mRNA levels in Beas-2B cells were significantly different from those in NL9980, L9981, 95C, 95D, H1299, H460, and YTMLC-90 cells (P<0.001), and also significantly different from those in SPC-A-1 cells (P<0.05) (Table 1). Figure 1 B); There were no significant differences in PD-L1 mRNA levels between 95D cells and YTMLC-90 cells, and between H460 cells and YTMLC-90 cells (P>0.05), while significant differences in PD-L1 mRNA levels were observed between all other cell types (P<0.05) (Table 1). Figure 1 ).
[0036] Table 1. PD-L1 mRNA levels in different types of lung cancer cells as determined by qRT-PCR.
[0037]
[0038]
[0039] *YTM: YTMLC-90cell line; **P values are compared with Beas-2B cells.
[0040] Therefore, we selected three cell lines with relatively high PD-L1 expression—H1299, NL9980, and L9981—for subsequent experiments.
[0041] Experimental Example 2: Effect of ZQH2019818551220 on PD-L1 protein expression in lung cancer cell lines with different metastatic potentials
[0042] 2.1 Comparison of PD-L1 expression levels among different concentrations of ZQH2019818551220 treatment groups in the H1299 lung cancer cell line
[0043] After treating H1299 lung cancer cell lines with different concentrations of ZQH2019818551220 (0 / ml, 90 / ml, 180 / ml, 360μM / ml) for 72 hours, the PD-L1 expression levels among the groups showed highly significant differences (P<0.001) according to the F test. Pairwise comparisons: (1) There were highly significant differences in PD-L1 expression levels between the 0μM / ml ZQH2019818551220 treatment group and the 180 / ml and 360μM / ml treatment groups (P<0.001), but there was no significant difference between the 0μM / ml ZQH2019818551220 treatment group and the 90μM / ml treatment group (P>0.05) (Table 2). Figure 2 (2) There was a significant difference in PD-L1 expression levels between the 90 μM / ml ZQH2019818551220 treatment group and the 180 μM / ml and 360 μM / ml treatment groups (P<0.05) (Table 2); (3) There was no significant difference in PD-L1 expression levels between the 180 μM ZQH2019818551220 treatment group and the 360 μM treatment group (P>0.05) (Table 2).
[0044] 2.2 Comparison of PD-L1 expression levels among different concentrations of ZQH2019818551220 treatment groups in the NL9980 lung cancer cell line
[0045] After treating NL9980 lung cancer cell lines with different concentrations of ZQH2019818551220 (0 / ml, 90 / ml, 180 / ml, 360μM / ml) for 72 hours, the PD-L1 expression levels among the groups showed highly significant differences (P<0.001) according to the F test; pairwise comparisons: (1) There was no significant difference in PD-L1 expression levels between the 0μM / ml ZQH2019818551220 treatment group and the 90μM / ml treatment group (P>0.05) (Table 2, Figure 2 (1) The 0 μM / ml ZQH2019818551220 treatment group showed a highly significant difference compared with the 180 μM / ml and 360 μM / ml treatment groups (P<0.001); (2) There was no significant difference in PD-L1 expression levels between the 90 μM / ml ZQH2019818551220 treatment group and the 180 μM / ml treatment group (P>0.05) (Table 2), but a highly significant difference compared with the 360 μM / ml treatment group (P<0.001); (3) There was a highly significant difference between the 180 μM / ml ZQH2019818551220 treatment group and the 360 μM / ml treatment group (P<0.001) (Table 2, Figure 2 ).
[0046] 2.3 Comparison of PD-L1 expression levels among different concentrations of ZQH2019818551220 treatment groups in the L9981 lung cancer cell line
[0047] After treating L9981 lung cancer cell lines with different concentrations of ZQH2019818551220 (0 / ml, 90 / ml, 180 / ml, 360μM / ml) for 72 hours, the PD-L1 expression levels among the groups showed highly significant differences (P<0.001) according to the F test; pairwise comparisons: (1) The PD-L1 expression levels in the 0μM / ml ZQH2019818551220 treatment group were significantly different from those in the 90 / ml, 180 / ml, and 360μM / ml treatment groups (P<0.001) (Table 2, Figure 2 (2) There was no significant difference in PD-L1 expression levels between the 90 μM / ml ZQH2019818551220 treatment group and the 180 μM / ml treatment group (P>0.05) (Table 2), but there was a significant difference between the 90 μM / ml ZQH2019818551220 treatment group and the 360 μM / ml treatment group (P<0.05) (Table 2). Figure 2 ).
[0048] 2.4 Comparison of PD-L1 expression levels among different lung cancer cell lines after treatment with the same concentration of ZQH2019818551220
[0049] 2.4.1 Comparison of PD-L1 expression levels among H1299, NL9980, and L9981 lung cancer cell lines after treatment with 0 μM / ml ZQH2019818551220 for 72 hours
[0050] After treatment with 0 μM / ml ZQH2019818551220 for 72 hours, there was no significant difference in PD-L1 expression levels among H1299, NL9980, and L9981 lung cancer cell lines (P>0.05, according to the F-test) (Table 2). Figure 2 ).
[0051] 2.4.2 Comparison of PD-L1 expression levels among H1299, NL9980, and L9981 lung cancer cell lines after treatment with 90 μM / ml ZQH2019818551220 for 72 hours
[0052] After treatment with 90 μg / ml ZQH2019818551220 for 72 hours, the PD-L1 expression levels of H1299, NL9980, and L9981 lung cancer cell lines showed significant differences (P<0.05) according to the F test. Pairwise comparisons showed no significant difference in PD-L1 expression levels between H1299 and NL9980 lung cancer cell lines (P>0.05), but highly significant differences (P<0.001) were observed between NL9980 and L9981 lung cancer cell lines, and between H1299 and L9981 lung cancer cell lines (Table 2). Figure 2 ).
[0053] 2.4.3. Comparison of PD-L1 expression levels among H1299, NL9980, and L9981 lung cancer cell lines after treatment with 180 μM / ml ZQH2019818551220 for 72 hours.
[0054] After treatment with 180 μM / ml ZQH2019818551220 for 72 hours, the PD-L1 expression levels of H1299, NL9980, and L9981 lung cancer cell lines showed significant differences (P<0.05) according to the F-test. Pairwise comparisons showed highly significant differences in PD-L1 expression levels between H1299 and NL9980 lung cancer cell lines (P<0.001), between NL9980 and L9981 lung cancer cell lines (P<0.001), and between H1299 and L9981 lung cancer cell lines (P<0.05) (Table 2). Figure 2 ).
[0055] 2.4.4. Comparison of PD-L1 expression levels among H1299, NL9980, and L9981 lung cancer cell lines after treatment with 360 μM / ml ZQH2019818551220 for 72 hours.
[0056] After treatment with 360 μM / ml ZQH2019818551220 for 72 hours, the PD-L1 expression levels of H1299, NL9980, and L9981 lung cancer cell lines showed significant differences (P<0.05) according to the F-test. Pairwise comparisons showed significant differences in PD-L1 protein levels between the H1299 and NL9980 groups, the NL9980 and L9981 groups, and the H1299 and L9981 groups (P<0.05) (Tables 2 and 3). Figure 2 ).
[0057] Table 2. PD-L1 protein levels in lung cancer cells after treatment with different concentrations of ZQH2019818551220 by Western Blot.
[0058]
[0059] Table 3. PD-L1 fluorescence intensity of lung cancer cells after treatment with different concentrations of ZQH2019818551220 by flow cytometry.
[0060]
[0061] Comparison of PD-L1 expression levels at different time points after treatment with 360 μM / ml ZQH2019818551220 in 2.5H1299 lung cancer cell line
[0062] After treating H1299 lung cancer cell lines with 360 μM / ml ZQH2019818551220 for 0, 24, 48, and 72 hours respectively, the PD-L1 expression levels among the groups showed highly significant differences (P<0.001) according to the F test; pairwise comparisons: (1) There was no significant difference in PD-L1 expression levels between the initial control group and the 24h treatment group (P>0.05), but there were highly significant differences compared with the 48 and 72h treatment groups (P<0.001) (Table 4, Figure 2 (2) There was a very significant difference in the expression level of PD-L1 in cells between the 24h treatment group and the 48 and 72μM treatment groups (P<0.001) (Table 4); (3) There was no significant difference in the expression level of PD-L1 in cells between the 48h treatment group and the 72h treatment group (P>0.05) (Table 3).
[0063] 2.6 Comparison of PD-L1 expression levels at different time points after treatment with 360 μM / ml ZQH2019818551220 in NL9980 lung cancer cell line
[0064] After treating NL9980 lung cancer cell lines with 360 μM / ml ZQH2019818551220 for 0, 24, 48, and 72 hours respectively, the PD-L1 expression levels among the groups showed highly significant differences (P<0.001) according to the F test; pairwise comparisons: (1) There was a significant difference in PD-L1 expression levels between the initial control group and the 24h treatment group (P<0.05), and highly significant differences compared with the 48 and 72h treatment groups (P<0.001) (Table 4, Figure 2(2) There was a very significant difference in the expression level of PD-L1 in cells between the 24h treatment group and the 48 and 72μM treatment groups (P<0.001) (Table 4); (3) There was a significant difference in the expression level of PD-L1 in cells between the 48h treatment group and the 72h treatment group (P<0.05) (Table 4).
[0065] Comparison of PD-L1 expression levels at different time points after treatment with 360 μM / ml ZQH2019818551220 L9981 lung cancer cell line.
[0066] After treating L9981 lung cancer cell lines with 360 μM / ml ZQH2019818551220 for 0, 24, 48, and 72 hours, the PD-L1 expression levels among the groups showed highly significant differences (P<0.001) according to the F test. Pairwise comparisons: (1) There was no significant difference in PD-L1 expression levels between the initial control group and the 24h treatment group (P>0.05), but there were highly significant differences compared with the 48h and 72h treatment groups (P<0.001) (Table 4). Figure 2 (2) There was a very significant difference between the 24h treatment group and the 48h and 72h treatment groups (P<0.001); (3) There was a very significant difference in PD-L1 expression level between the 48h treatment group and the 72h treatment group (P<0.001) (Table 4).
[0067] 2.8 Comparison of PD-L1 expression levels among different lung cancer cell lines at the same time point using ZQH2019818551220 at 360 μM / ml
[0068] 2.8.1. Comparison of PD-L1 expression levels at the start of 360 μM ZQH2019818551220 treatment among H1299, NL9980, and L9981 lung cancer cell lines.
[0069] Among the H1299, NL9980, and L9981 lung cancer cell lines treated with ZQH2019818551220 as the initial treatment group, there was no significant difference in PD-L1 expression levels according to the F-test (P>0.05) (Table 4). Figure 2 ).
[0070] 2.8.2. Comparison of PD-L1 expression levels among H1299, NL9980, and L9981 lung cancer cell lines after treatment with 360 μM / ml ZQH2019818551220 for 24 hours.
[0071] After treatment with 360 μM / ml ZQH2019818551220 for 24 hours, the PD-L1 expression levels of H1299, NL9980, and L9981 lung cancer cell lines showed significant differences (P<0.05) according to the F test. Pairwise comparisons showed significant differences in PD-L1 expression levels between H1299 and NL9980 lung cancer cell lines, and between H1299 and L9981 lung cancer cell lines (P<0.05), but no significant difference in PD-L1 expression levels between NL9980 and L9981 lung cancer cell lines (P>0.05) (Table 4). Figure 2 ).
[0072] 2.8.3. Comparison of PD-L1 expression levels among H1299, NL9980, and L9981 lung cancer cell lines after treatment with 360 μM / ml ZQH20198185512201 for 48 hours.
[0073] After treatment with 360 μM / ml ZQH20198185512201 for 48 hours, there was no significant difference in PD-L1 expression levels among H1299, NL9980, and L9981 lung cancer cell lines (P>0.05) (Table 4). Figure 2 ).
[0074] 2.8.4. Comparison of PD-L1 expression levels among H1299, NL9980, and L9981 lung cancer cell lines after treatment with 360 μM / ml ZQH2019818551220 for 72 hours.
[0075] After treatment with 360 μM / ml ZQH2019818551220 for 72 hours, the PD-L1 expression levels of H1299, NL9980, and L9981 lung cancer cell lines showed significant differences (P<0.05) according to the F-test. Pairwise comparisons of PD-L1 expression levels among the three groups also showed significant differences (P<0.05) (Table 4). Figure 2 Table 4 shows the PD-L1 protein levels in lung cancer cells at different time points after treatment with 360 μM / ml ZQH2019818551220 by Western Blot.
[0076]
[0077]
[0078] Experimental Example 3: Effect of ZQH2019818551220 on PD-L1 mRNA levels in lung cancer cell lines with different metastatic potentials
[0079] 3.1 Comparison of PD-L1 mRNA levels among different concentrations of ZQH2019818551220 treatment groups in H1299 lung cancer cell line
[0080] After treating H1299 lung cancer cell lines with different concentrations of ZQH2019818551220 (0 μM / ml, 90 μM / ml, 180 μM / ml, 360 μM / ml) for 72 hours, the PD-L1 mRNA expression levels among the groups showed highly significant differences according to the F test (P<0.001); pairwise comparisons: (1) There were highly significant differences in PD-L1 mRNA levels between the 0 μM / ml ZQH2019818551220 treatment group and the 90, 180, and 360 μM / ml treatment groups (P<0.001) (Table 5, Figure 3 (2) There was a significant difference in PD-L1 mRNA levels between the 90 μM / ml ZQH2019818551220 treatment group and the 180 μM / ml and 360 μM / ml treatment groups (P<0.05) (Table 5); (3) There was no significant difference in PD-L1 mRNA expression levels between the 180 μM / ml ZQH2019818551220 treatment group and the 360 μM / ml treatment group (P>0.05) (Table 5).
[0081] 3.2 Comparison of PD-L1 mRNA expression levels among different concentrations of ZQH2019818551220 treatment groups in the NL9980 lung cancer cell line
[0082] After treating NL9980 lung cancer cell lines with different concentrations of ZQH2019818551220 (0, 90, 180, 360 μM / ml) for 72 hours, the PD-L1 mRNA expression levels among the groups showed highly significant differences (P<0.001) according to the F test; pairwise comparisons: (1) There were highly significant differences between the 0 μM / ml ZQH2019818551220 treatment group and the 90, 180, and 360 μM / ml treatment groups (P<0.001) (Table 5, Figure 3 (2) There was no significant difference in PD-L1 mRNA expression levels between the 90 μM / ml ZQH2019818551220 treatment group and the 180 μM / ml treatment group (P>0.05) (Table 5), but there was a highly significant difference between the 90 μM / ml ZQH2019818551220 treatment group and the 360 μM / ml treatment group (P<0.05) (Table 5). Figure 3 ).
[0083] 3.3 Comparison of PD-L1 mRNA expression levels among different concentrations of ZQH2019818551220 treatment groups in the L9981 lung cancer cell line
[0084] After treating L9981 lung cancer cell lines with different concentrations of ZQH2019818551220 (0, 90, 180, 360 μM / ml) for 72 hours, the PD-L1 mRNA expression levels among the groups showed highly significant differences (P<0.001) according to the F test; pairwise comparisons: (1) The PD-L1 mRNA expression levels in the 0 μM / ml ZQH2019818551220 treatment group were significantly different from those in the 90, 180, and 360 μM / ml treatment groups (P<0.001) (Table 5, Figure 3 (2) There was no significant difference in PD-L1 mRNA expression levels between the 90 μM / ml ZQH2019818551220 treatment group and the 180 μM / ml treatment group (P>0.05) (Table 5), but there was a significant difference between the 90 μM / ml ZQH2019818551220 treatment group and the 360 μM / ml treatment group (P<0.05); (3) There was a significant difference in PD-L1 mRNA expression levels between the 180 μM / ml ZQH2019818551220 treatment group and the 360 μM / ml treatment group (P<0.05) (Table 5). Figure 3 ).
[0085] 3.4 Comparison of PD-L1 mRNA expression levels among different lung cancer cell lines with the same concentration of ZQH2019818551220
[0086] 3.4.1. Comparison of PD-L1 mRNA expression levels among H1299, NL9980, and L9981 lung cancer cell lines after treatment with 0 μM / ml ZQH2019818551220 for 72 hours.
[0087] After treatment with 0 μM / ml ZQH2019818551220 for 72 hours, the PD-L1 mRNA expression levels among H1299, NL9980, and L9981 lung cancer cell lines showed highly significant differences (P<0.001) according to the F-test. Pairwise comparisons showed highly significant differences (P<0.001) in PD-L1 mRNA levels between the H1299 and NL9980 groups, the NL9980 and L9981 groups, and the H1299 and L9981 groups (Table 5). Figure 3 ).
[0088] 3.4.2. Comparison of PD-L1 mRNA levels among H1299, NL9980, and L9981 lung cancer cell lines after treatment with 90 μM / ml ZQH2019818551220 for 72 hours.
[0089] After treatment with 90 μM / ml ZQH2019818551220 for 72 hours, the PD-L1 mRNA levels of H1299, NL9980, and L9981 lung cancer cell lines showed highly significant differences (P<0.001) according to the F test. Pairwise comparisons showed significant differences in PD-L1 mRNA levels between H1299 and NL9980 lung cancer cell lines (P<0.05), highly significant differences in PD-L1 mRNA expression levels between NL9980 and L9981 lung cancer cell lines, and between H1299 and L9981 lung cancer cell lines (P<0.001) (Table 5). Figure 3 ).
[0090] 3.4.3. Comparison of PD-L1 mRNA expression levels among H1299, NL9980, and L9981 lung cancer cell lines after treatment with 180 μM / ml ZQH2019818551220 for 72 hours.
[0091] After treatment with 180 μM / ml ZQH2019818551220 for 72 hours, the expression levels of PD-L1 mRNA in lung cancer cell lines H1299, NL9980, and L9981 showed highly significant differences (P<0.001) according to the F test. Pairwise comparisons showed highly significant differences (P<0.001) in PD-L1 mRNA expression levels between H1299 and NL9980, NL9980 and L9981, and H1299 and L9981 lung cancer cell lines (Table 5). Figure 3 ).
[0092] 3.4.4. Comparison of PD-L1 mRNA expression levels among H1299, NL9980, and L9981 lung cancer cell lines after treatment with 360 μM / ml ZQH2019818551220 for 72 hours.
[0093] After treatment with 360 μM / ml ZQH2019818551220 for 72 hours, the expression levels of PD-L1 mRNA in H1299, NL9980, and L9981 lung cancer cell lines showed significant differences (P<0.05) according to the F test. Pairwise comparisons showed significant differences in PD-L1 mRNA expression levels between H1299 and NL9980 lung cancer cell lines (P<0.05), and highly significant differences (P<0.001) between NL9980 and L9981 lung cancer cell lines, as well as between H1299 and L9981 lung cancer cell lines (Table 5). Figure 3 ).
[0094] Table 5. Detection of PD-L1 mRNA expression levels in lung cancer cells after treatment with different concentrations of ZQH2019818551220 by qRT-PCR.
[0095]
[0096] Experimental Example 4: Effects of ZQH2019818551220 on the PI3K-AKT signaling pathway in lung cancer cell lines with different metastatic potential
[0097] 4.1ZQH2019818551220 Suppressing the PI3K-AKT signaling pathway
[0098] We used Western blotting to detect whether the PI3K-AKT pathway was inhibited in the ZQH2019818551220 PD-L1 downregulation system in this study, and to verify whether the alteration of this pathway was related to the downregulation of PD-L1. Western blotting results showed that after treatment with 180 and 360 μM / ml ZQH2019818551220 for 72 hours, p-AKT expression was significantly reduced compared to the control group. Figure 4 The results showed that treatment with 180 and 360 μM ZQH2019818551220 for 72 hours significantly inhibited the PI3K-AKT pathway in lung cancer cells.
[0099] 4.2 Using the AKT activator SC79, it was demonstrated that ZQH2019818551220 downregulates PD-L1 expression by inhibiting the AKT signaling pathway.
[0100] The AKT activator SC79 can selectively activate the PI3K-AKT pathway, promoting AKT phosphorylation. We added SC79 to the system in which ZQH2019818551220 downregulated PD-L1 to explore whether the PI3K-AKT pathway plays a role in the downregulation of PD-L1 by ZQH2019818551220. The experiment was designed with four treatment groups. The fourth group was pretreated with 10 μM / ml AKT activator SC79 for 1 hour, followed by treatment with 360 μM / ml ZQH2019818551220 for 72 hours. The other three groups were pretreated with DMSO followed by treatment with ZQH2019818551220 solvent (original water for injection), pretreated with SC79 followed by treatment with ZQH2019818551220 solvent, and pretreated with DMSO followed by treatment with ZQH2019818551220. The solute, solvent concentration, and treatment time of each group were consistent with those of the fourth group. Total protein was extracted and Western blot analysis was performed. The results showed that: (1) SC79 upregulated p-AKT protein expression, while total AKT protein did not change significantly, promoting AKT phosphorylation activation; (2) In the ZQH2019818551220 single-drug treatment group, the PD-L1 protein band signal was weak, while in the ZQH2019818551220 combined with SC79 treatment group, the PD-L1 protein band signal was stronger than that of the former. Figure 4 This suggests that ZQH2019818551220 may downregulate PD-L1 expression in lung cancer cells through the PI3K-AKT pathway.
[0101] Experimental Example 5: Effects of ZQH2019818551220 on PD-L1-related transcription factors in lung cancer cell lines with different metastatic potentials
[0102] 5.1 Western Blot analysis of changes in relevant transcription factors after treatment with ZQH2019818551220
[0103] Given that ZQH2019818551220 not only downregulates PD-L1 protein but also upregulates and upregulates PD-L1 mRNA at the transcriptional level, we used Western blotting to detect changes in related transcription factors in lung cancer cells after treatment with ZQH2019818551220. The results showed that after 72 hours of treatment with 360 μM / ml ZQH2019818551220, p-STAT3 was significantly reduced, but the representative component of NF-κB, p65, the representative component of AP-1, pc-jun, and HIF-1α did not show significant changes. Figure 5 This suggests that STAT3 may be an important molecule regulating PD-L1 transcription (ZQH2019818551220).
[0104] To verify whether ZQH2019818551220 treatment affected STAT3 nuclear translocation, H1299, NL9980, and L9981 lung cancer cells were treated with 360 μM / ml ZQH2019818551220 and the same amount of solvent, respectively. Nuclear and plasma proteins were extracted using nuclear-cytoplasmic separation, and the concentration of STAT3-related proteins was detected by Western blotting. The results showed that compared with the control group, the ZQH2019818551220 treatment group had significantly lower levels of p-STAT3 and total STAT3 proteins in the nucleus, with a larger decrease; while the total STAT3 in the cytoplasm did not decrease significantly, and even increased slightly. Figure 5 This indicates that treatment of lung cancer cells with 360 μM / ml ZQH2019818551220 can also significantly inhibit the nuclear translocation of transcription factor STAT3.
[0105] 5.2 Using the STAT3 activator Colivelin, it was demonstrated that ZQH2019818551220 downregulates PD-L1 by inhibiting STAT3.
[0106] To demonstrate that ZQH2019818551220 downregulates PD-L1 expression by inhibiting the activation of transcription factor STAT3, we added the STAT3 activator Colivelin to the system in which ZQH2019818551220 downregulated PD-L1, and explored the role of STAT3 in the downregulation of PD-L1 by ZQH2019818551220. Similar to the experimental design of SC79 combined with ZQH2019818551220 mentioned above, the experiment was divided into four treatment groups. The fourth group was treated with lung cancer cells by pretreating them with 0.5 μM / ml of the STAT3 activator Colivelin for 1 hour, followed by treatment with 360 μM / ml of ZQH2019818551220 for 72 hours. The other three groups were pretreated with DMSO and then treated with ZQH2019818551220 solvent (original water for injection), pretreated with Colivelin and then treated with ZQH2019818551220 solvent, and pretreated with DMSO and then treated with ZQH2019818551220. The solute, solvent concentration and treatment time of each group were consistent with the fourth group. Total protein was extracted and analyzed by Western blotting. The results showed that in the ZQH2019818551220 single-drug treatment group, the PD-L1 protein level was significantly lower than that in the control group. In the ZQH2019818551220 combined with Colivelin treatment group, the PD-L1 protein level partially recovered, but was still lower than that in the control group. Figure 6This suggests that ZQH2019818551220 may downregulate PD-L1 expression by inhibiting the activation of the transcription factor STAT3 in lung cancer cells.
[0107] Example 6: Construct a dual-luciferase reporter plasmid containing the promoter region of CD274 (the gene encoding PD-L1) to verify that ZQH2019818551220 regulates CD274 transcription through the AKT-STAT3 pathway.
[0108] 6.1 Identification of the dual-luciferase reporter plasmid insertion sequence containing the CD274 promoter region
[0109] In the experimental methods section, we have already introduced the steps for preparing the dual-luciferase reporter plasmid. The final identification was performed using two methods: restriction enzyme digestion and sequencing. The results of the restriction enzyme digestion method are as follows: After digestion with restriction endonucleases Kpn I and Sac I, two DNA bands were observed on the DNA agarose gel, one in the 1-2 kb range and the other at 5 kb. Figure 7 The sequence indicates that the recombinant contains a 1369kb target fragment. Further sequencing identification results are shown in the figure below. Figure 6 After checking the bases, it was confirmed that the sequence was completely identical to the promoter region of the CD274 gene. This plasmid can be used for subsequent dual-luciferase reporter assays.
[0110] 6.2 Using a dual-luciferase reporter plasmid, we verified that ZQH2019818551220 inhibited PD-L1 transcription.
[0111] After transfection with a dual-luciferase reporter plasmid, three lung cancer cell lines were treated with 0, 90, 180, and 360 μM / ml ZQH2019818551220 for 72 hours. Cells from each group were then recovered for dual-luciferase reporter assay. Results showed that in all three lung cancer cell lines, the relative luciferase activity in the 180 and 360 μM / ml treatment groups was significantly lower than that in their respective control groups, and the decrease increased with increasing dosage. Figure 7 This result is consistent with the results of ZQH2019818551220, which showed downregulation of PD-L1 protein and mRNA levels, thus validating the above experiments.
[0112] 6.3 Using a dual-luciferase reporter plasmid, it was verified that ZQH2019818551220 inhibits STAT3 transcription of PD-L1 by inhibiting AKT.
[0113] To demonstrate whether the attenuation of PI3K / AKT signaling inhibits STAT3 transcription of PD-L1 upstream, we added the AKT activator SC79 to the ZQH2019818551220 system that downregulated PD-L1 and observed the changes in relative luciferase activity in lung cancer cells. We transfected lung cancer cells with a dual-luciferase reporter plasmid and, using the same experimental design, added the AKT activator SC79 to the ZQH2019818551220 system that downregulated PD-L1. We set up a control group, a ZQH2019818551220 monotherapy group, an SC79 monotherapy group, and a ZQH2019818551220+SC79 treatment group. After 72 hours of treatment, cells were recovered for dual-luciferase reporter assay. The results showed that the relative luciferase activity in the SC79 monotherapy group was significantly higher than that in the control group, while the relative luciferase activity in the ZQH2019818551220+SC79 combined treatment group was somewhat recovered compared with the ZQH2019818551220 monotherapy group. Figure 7 This result further confirms that ZQH2019818551220 inhibits STAT3 transcription of PD-L1 by suppressing the AKT pathway.
[0114] 6.4 Using a dual-luciferase reporter plasmid, it was demonstrated that ZQH2019818551220 inhibits transcription factor STAT3, leading to a decrease in PD-L1 transcription levels.
[0115] The aforementioned experiments demonstrated that among the major transcription factors of PD-L1, STAT3 is the only one significantly inhibited by ZQH2019818551220. Therefore, treating lung cancer cells transfected with dual-luciferase cells with a combination of STAT3 activator and ZQH2019818551220, and observing changes in relative luciferase activity, strongly suggests that the inhibition of transcription factor STAT3 is related to the downregulation of PD-L1 transcription.
[0116] Dual-luciferase reporter plasmids were transfected into lung cancer cells. Using the same experimental design, the STAT3 activator Colivelin was added to the system where ZQH2019818551220 downregulated PD-L1. Control, ZQH2019818551220 monotherapy, Colivelin monotherapy, and ZQH2019818551220 + Colivelin therapy were established. After 72 hours of treatment, cells were recovered for dual-luciferase reporter assay. The results showed that the relative luciferase activity in the Colivelin monotherapy group was significantly higher than that in the control group, while the relative luciferase activity in the ZQH2019818551220 + Colivelin combination therapy group was somewhat recovered compared to the ZQH2019818551220 monotherapy group. Figure 7The results suggest that: (1) the transcription factor STAT3 can bind to the PD-L1 promoter region and participate in the transcription process of PD-L1; (2) ZQH2019818551220 inhibits PD-L1 transcription by inhibiting the activation of the transcription factor STAT3.
[0117] Experimental Example 7: Effect of ZQH2019818551220 on Tumorigenicity of Lung Cancer Xenografts in Nude Mice 7.1 Comparison of Tumor Volume between the ZQH2019818551220 Treatment Group and the Control Group in Nude Mice
[0118] The changes in tumor volume during tumor growth in nude mice treated with ZQH2019818551220 and the control group were statistically analyzed, and tumor volume growth curves were constructed. The results showed that, for both H1299-luc and L9981-luc xenografts, after 36 days of treatment, the T-test showed that the tumor volume in the ZQH2019818551220 treatment group was significantly lower than that in the control group (P<0.001). The average tumor volume in the ZQH2019818551220 treatment group was only about 1 / 3 to 1 / 4 of that in the control group (Table 6). Figure 8 After the experiment, the xenografts in the nude mice were removed, and the above measurement results were confirmed by visual inspection and measurement. Figure 8 The results showed that after 36 days of treatment with ZQH2019818551220 at a dose of 20 mg / kg / d, the growth of xenografts in nude mice was significantly inhibited.
[0119] Table 6. Tumor volume of H1299-luc and L9981-luc xenografts in nude mice 36 days after administration of ZQH2019818551220.
[0120]
[0121] 7.2ZQH2019818551220 After administration of the drug, the tumor weight in nude mice decreased significantly, but the body weight of the nude mice did not decrease significantly.
[0122] After the medication was administered, the nude mice were weighed, and the transplanted tumors were removed and weighed. Results showed that, according to t-test analysis, the tumor weight in the ZQH2019818551220 medication group was significantly lower than that in the control group (P<0.001), but there was no significant difference in the average weight of the nude mice between the two groups (P>0.05) (Tables 7 and 8). Figure 8 In nude mice with H1299-luc xenograft tumors, the average tumor weight in the ZQH2019818551220 treatment group was approximately one-quarter that of the control group; in nude mice with L9981-luc xenograft tumors, the average tumor weight in the ZQH2019818551220 treatment group was only about one-tenth that of the control group (Table 7). Figure 8In addition, after 36 days of treatment with ZQH2019818551220, the mental state and motor ability of nude mice in the ZQH2019818551220 treatment group were improved compared with the control group, while skin color and food and water intake were not significantly different from the control group. Figure 8 The results suggest that nude mice tolerated ZQH2019818551220 at 20 mg / kg / d for 36 days without significant toxic side effects, and the growth of the transplanted tumor was significantly inhibited.
[0123] 7.3 Using in vivo imaging technology, the luciferase activity of orthotopic xenograft tumors in nude mice was compared between the ZQH2019818551220 treatment group and the control group.
[0124] To monitor the activity of tumor cells in orthotopic xenografts and metastases in real time, we used an IVIS-200 in vivo imaging system to detect fluorescence intensity within the xenografts. Results showed that luciferase activity in the orthotopic xenografts of the ZQH2019818551220 treatment group was significantly lower than that in the control group, as observed by naked-eye observation of in vivo images. Luciferase activity was measured in each group, relative luciferase activity was calculated, and bar charts were plotted for statistical analysis. T-test results showed that in H1299-luc nude mice, the luciferase activity in the ZQH2019818551220 treatment group was significantly lower than that in the control group (P<0.05), with an average reduction of approximately one-third or more. Similarly, in L9981-luc nude mice, the luciferase activity in the ZQH2019818551220 treatment group was also significantly lower than that in the control group (P<0.05), with the average luciferase activity in the treatment group being only about half that of the control group (Table 9). Figure 9 This indicates that ZQH2019818551220 significantly inhibited the cell activity of orthotopic xenografts.
[0125] Table 7 Body weight of nude mice with H1299-luc and L9981-luc xenografts 36 days after administration of ZQH2019818551220
[0126]
[0127] Table 8. Tumor weight of H1299-luc and L9981-luc xenografts 36 days after administration of ZQH2019818551220
[0128]
[0129] Table 9. Luciferase activity of orthotopic tumors of H1299-luc and L9981-luc 36 days after administration of ZQH2019818551220.
[0130]
[0131] Experiment 8, Effect of ZQH2019818551220 on PD-L1 protein expression in lung cancer xenograft tissues of nude mice
[0132] To verify whether ZQH2019818551220 could also inhibit PD-L1 protein expression in lung cancer cells in vivo, we recovered fresh xenograft specimens, extracted tumor proteins, and used immunohistochemical staining to detect PD-L1 protein expression levels. The results showed that in both H1299-luc and L9981-luc xenografts, the PD-L1 protein levels in the ZQH2019818551220-treated group were significantly lower than those in the control group. Figure 10 This indicates that ZQH2019818551220 also significantly downregulated the expression of PD-L1 protein in tumors after tumor formation in nude mice.
[0133] In summary, this invention provides the use of AKT / STAT3 as a target for immune screening point inhibitors and offers a novel use for AKT / ATAT3 inhibitors. ZQH2019818551220, as a novel AKT / ATAT3 inhibitor, can significantly inhibit PD-L1 expression levels by inhibiting the activity of the AKT / STAT3 pathway (including the AKT pathway, PI3K / AKT pathway, and STAT3 pathway), thereby blocking the binding of PD-1 to PD-L1, restoring T cell activity, and thus enhancing the anti-tumor immune response of T cells; it can inhibit the in vitro proliferation of tumor cells and induce tumor cell apoptosis; in mouse lung cancer xenograft model experiments, this small molecule inhibitory compound was found to significantly inhibit the tumorigenicity of lung cancer xenografts.
[0134] Therefore, the AKT / STAT3 pathway is a novel immune checkpoint pathway that can be used to develop novel, highly effective, and low-toxicity immune checkpoint inhibitors for tumor immunotherapy. Furthermore, the AKT / STAT3 pathway immune checkpoint inhibitor of this invention can be used in combination with existing immune checkpoint inhibitors to block tumor immune escape through dual pathways, thereby enhancing the efficacy of immunotherapy and avoiding or / and mitigating drug resistance to single PD-1 immune checkpoint inhibitors.
Claims
1. The use of N-terminal acetyl-modified peptides in the preparation of inhibitors against PD-1 / PD-L1, characterized in that, The PD-1 / PD-L1 inhibitor is a drug for treating liver cancer, gastric cancer, cervical cancer, breast cancer, prostate cancer, nasopharyngeal carcinoma, colorectal cancer, oral cancer, or pancreatic cancer, and the sequence of the polypeptide is shown in SEQ ID NO.
1.
2. The use as described in claim 1, characterized in that, The PD-1 / PD-L1 inhibitor is an inhibitor that downregulates PD-L1 expression or an inhibitor that blocks the binding of PD-1 to PD-L1.
Citation Information
Patent Citations
Application of SHP2 inhibitor in preparing anti-tumor medicine
CN108113984A
